Tony Mok, BMSc, MD, FRCPC, FHKCP, FHKAM, FRCP, notes the implications of 7-year data from the CROWN study of frontline lorlatinib in ALK-positive NSCLC.
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO
Advertisement
Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, is chairman of the Department of Clinical Oncology and the Li Shu Fan Professor of Clinical Oncology at the Chinese University of Hong Kong
Articles by Tony S. K. Mok, MD, BMSc, FRCPC, FASCO
Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.
Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL
5